BioNJ members pledge paid time off for employees participating in clinical trials to enhance health equity.
Read more
FDA approves Attruby for reducing cardiovascular death and hospitalization in Transthyretin Amyloid Cardiomyopathy patients.
Read more
Eflornithine and lomustine improve survival in recurrent grade 3 IDH mutant astrocytoma, per Phase 3 STELLAR study.
Read more
Adcendo raises $135M to advance first-in-class ADCs for cancer treatment.
Read more
FDA approves Shorla's IMKELDI, an oral solution for treating Chronic Myeloid Leukemia and other cancers.
Read more
Citius Pharma's FDA meeting outlines NDA pathway for Mino-Lok in treating catheter-related bloodstream infections.
Read more
NIH advances stroke drug development with new clinical platform for preclinical study graduate.
Read more
Pfizer appoints Chris Boshoff as new R&D chief to revitalize oncology and innovation strategy.
Read more
Humacyte to present Phase 3 trial results on bioengineered vessels for End Stage Renal Disease at VEITH Symposium.
Read more
Vaping causes immediate negative effects on vascular function, similar to traditional smoking, even without nicotine.
Read more
Kyowa Kirin invests $330M in Kura's ziftomenib for Acute Myeloid Leukemia, aiming for FDA approval by 2025.
Read more
Boston Scientific to acquire Intera Oncology, enhancing liver cancer treatment with FDA-approved hepatic artery infusion therapy.
Read more
Adcendo raises $135M to advance ADC candidates targeting cancers with high unmet needs, including soft tissue sarcoma.
Read more
FDA approves StemCyte's REGENECYTE™ for hematopoietic stem cell therapy in blood and immune disorders.
Read more
FDA approves Ziihera for HER2-positive Biliary Tract Cancer, marking a milestone for Zymeworks' bispecific antibody technology.
Read more
FDA grants RMAT designation to Intellia's CRISPR therapy for Hereditary Transthyretin Amyloidosis with Polyneuropathy.
Read more
DNA sequencing market to reach $21.3 billion by 2031, driven by clinical applications and genomic projects.
Read more
Scinai's equity rises to $10M after EIB loan conversion; positive psoriasis trial feedback received.
Read more
InxMed's Ifebemtinib gains Breakthrough Therapy status for NSCLC with KRAS G12C mutation in China.
Read more
Alpheus Medical's sonodynamic therapy doubles survival in Phase 1/2 trial for recurrent high-grade gliomas.
Read more
Zai Lab and Pfizer collaborate to commercialize XACDURO® for carbapenem-resistant Acinetobacter baumannii in China.
Read more
EndoTheia's FlexStone Basket completes successful trial, enhancing precision in kidney stone removal.
Read more
Plus Therapeutics' CNSide assay improves diagnosis and management of Leptomeningeal Metastases, showing 2.8x sensitivity over standard cytology.
Read more
Lineage Cell Therapeutics announces $66 million direct offering for cell therapy development.
Read more
Gilead acquires Aelix's HTI vaccine program after promising Phase 2 results for HIV treatment.
Read more
